Abstract：【Objective】 To investigate the efficacy of anlotinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and its effects on the tumor markers cancer antigen 125 (CA125) and matrix metalloproteinase-2 (MMP-2).【Methods】 A total of 87 patients with EGFR-positive NSCLC were enrolled. Among them, 41 patients received anlotinib treatment (the observation group), and 46 patients received conventional treatment (the control group). Clinical efficacy, immune function, adhesion molecules [soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1)], levels of CA125 and MMP-2 before and after treatment, incidence of adverse reactions, and survival outcomes were compared between the two groups.【Results】 The objective response rate (ORR) in the observation group was significantly higher than that in the control group (P<0.05). After treatment, the observation group showed higher level of CD3+/CD4+ T cells and a higher CD3+CD4+/CD3+CD8+ ratio, but a lower CD3+/CD8+ ratio compared with the control group (P<0.05). Levels of sICAM-1, sVCAM-1, CA125, and MMP-2 in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). The 3-month disease-free survival rate in the observation group was significantly higher than that in the control group (P<0.05).【Conclusion】 Anlotinib is safe and effective treatment for patients with EGFR-positive NSCLC. It can improve immune function and reduce tumor marker levels.
周雷, 李勇威, 姜晓洁, 赵亮. 安罗替尼治疗EGFR阳性非小细胞肺癌患者的疗效及对CA125、MMP-2水平的影响[J]. 医学临床研究, 2026, 43(2): 216-218.
ZHOU Lei, LI Yongwei, JIANG Xiaojie, ZHAO Liang. Efficacy of Anlotinib in the Treatment of EGFR-Positive Non-Small Cell Lung Cancer and its Effects on CA125 and MMP-2 Levels. JOURNAL OF CLINICAL RESEARCH, 2026, 43(2): 216-218.
2026, Vol. 43 
